ALGN
Align Technology, Inc.
Healthcare · Medical Instruments & Supplies · United States · Stock
Score Breakdown
Scored for Long-Term Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The aggregate model score of 31.8 is anchored primarily by the profitability sub-score of 12.0, which prevents a lower ranking, but is pulled down by three sub-scores — growth (8.5), financial health (8.0), and momentum (5.4) — all sitting well below the midpoint of their 0–20 range.
- The dividend sub-score of 0.0 confirms Align pays no dividend and generates no scoring contribution from free cash flow distribution, which meaningfully limits the total score ceiling for income-oriented scoring profiles.
- The theme sub-score of 0.0 indicates the model did not identify exposure to any of the tracked macro themes such as AI, aging population, or domestic manufacturing from the 10-K filing content, removing a scoring lever available to some healthcare peers.
Why Not Higher
- The momentum sub-score of 5.4 out of 20 is the primary ceiling constraint, reflecting that sequential quarterly improvements in revenue, earnings, and margins are not present in the FY2025 filing data — a critical requirement for a higher composite score.
- Both the growth and financial health sub-scores remain in the lower half of their respective ranges, meaning that even with solid profitability margins, the model cannot award a materially higher score without evidence of revenue re-acceleration and balance sheet improvement.
Data Confidence
7 / 10
High — most data fields present
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Align Technology, Inc. is a U.S.-based medical devices company best known for its Invisalign clear aligner system and iTero intraoral scanners, products that digitize and streamline orthodontic and restorative dental treatment. The company operates across consumer and professional dental channels globally, with revenues driven primarily by aligner case volumes sold to orthodontists and general practitioners. Its FY2025 10-K filing underpins this analysis, and the model score of 31.8/100 reflects a company that retains meaningful profitability but is facing measurable pressure across growth, momentum, and balance sheet dimensions simultaneously. The profitability sub-score of 12.0 is the single strongest contributor, suggesting net and operating margins remain above-average for the sector, but the growth sub-score of 8.5 and momentum sub-score of 5.4 indicate that top-line and earnings expansion have slowed materially on a year-over-year and sequential basis. The financial health sub-score of 8.0 points to a leverage and interest coverage profile that warrants monitoring, and the absence of any dividend (0.0) or identifiable macro theme exposure (0.0) removes two common scoring boosts. The central research tradeoff is between Align's durable brand position and margin structure on one side, and its decelerating growth trajectory and lack of identifiable near-term re-acceleration catalysts on the other.
Plain English
Align Technology makes Invisalign braces — the clear plastic teeth-straightening trays you see advertised everywhere — along with digital scanners used by dentists. The model score of 31.8 out of 100 is below average, meaning the filing data shows the company is not currently growing quickly and its quarterly financial momentum is weak. The Medium risk rating means it is not an extreme high-risk situation, but there are enough financial headwinds that a researcher would want to watch rather than immediately rely on it as a core holding idea. It is labelled 'Monitor Only,' which reflects the current gap between a decent profitability baseline and sluggish growth.
Bull Case vs. Bear Case
Bull Case
- The profitability sub-score of 12.0 out of 20 indicates that Align Technology continues to generate meaningful net and operating margins relative to sector peers, suggesting its core Invisalign and iTero scanner business retains pricing power even in a softer volume environment.
- Align's integrated ecosystem of aligners, intraoral scanners, and digital workflow software creates switching costs for dental practices, which could support margin resilience and eventual volume recovery as orthodontic demand cycles normalize.
- The best scoring profile for this ticker is long-term growth at 36.8, suggesting the model sees a more constructive fundamental picture when evaluated against a longer time horizon rather than near-term momentum metrics.
Bear Case
- The growth sub-score of 8.5 out of 20 signals that year-over-year revenue, net income, and EPS expansion have deteriorated materially, indicating Align is not currently delivering the top-line compounding expected of a premium medical device franchise.
- The momentum sub-score of 5.4 out of 20 — the weakest fundamental sub-score — reflects sequential quarterly deterioration in revenue, earnings, or margins within the FY2025 filing period, suggesting the slowdown is not yet stabilizing.
- The financial health sub-score of 8.0 out of 20 points to leverage or interest coverage metrics that have become less comfortable, reducing the balance sheet cushion available to fund growth investments or weather further demand weakness.
What Could Change the Picture
Bullish Triggers
- A meaningful improvement in the momentum sub-score — driven by sequential quarterly revenue and earnings growth in future filings — would signal that Align's volume recovery is underway and would likely push the composite score above 40.
- Evidence of deleveraging or materially improved interest coverage in the next annual 10-K filing would strengthen the financial health sub-score and reduce the dual-pressure risk flag currently embedded in the model output.
Bearish Triggers
- Further deterioration in the growth sub-score below 8.5, reflecting additional year-over-year revenue or EPS declines, would lower the composite score and could shift the research label from 'Monitor Only' toward a more cautious designation.
- Any additional increase in leverage ratios or decline in interest coverage visible in future SEC filings would compound the financial health concern and reduce the balance sheet buffer available to Align during a prolonged demand downturn.
Red Flags
- The momentum sub-score of 5.4 is notably low and suggests that quarterly financial trends within the FY2025 filing are deteriorating rather than recovering, which is a meaningful concern for a growth-oriented medical device company.
- A financial health sub-score of 8.0 alongside a growth sub-score of 8.5 creates a dual pressure scenario where Align may face constrained reinvestment capacity precisely when it needs to stimulate volume recovery.
Risk Profile
Medium RiskThe Medium risk rating reflects that Align Technology's filing data shows a combination of decelerating growth, weak sequential momentum, and a balance sheet that is under more pressure than its profitability margins alone would suggest — creating moderate fundamental uncertainty without yet reaching the leverage or liquidity extremes that would warrant a High risk designation.
Key Catalysts to Watch
The key factors to watch in future SEC filings are sequential quarterly volume trends for Invisalign case shipments and iTero scanner revenues, which would drive an improvement in the momentum sub-score, and any material change in the debt or interest coverage structure that would shift the financial health sub-score in either direction.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.